INGELHEIM, GERMANY — Boehringer Ingelheim announced that the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP) has given a positive opinion for SCOVELLA®, an oral solution designed to reduce hyperinsulinaemia in insulin-dysregulated horses. This condition is a key driver of laminitis, a painful inflammatory disease affecting horses' hooves and a major cause of disability and euthanasia. SCOVELLA® would be the first therapy approved in the European Union to reduce hyperinsulinaemia and the associated risk of laminitis in horses with Equine Metabolic Syndrome once authorized by the European Commission.

Equine Metabolic Syndrome includes insulin dysregulation, which is linked to over 90% of laminitis cases, affecting about one in five horses. SCOVELLA® works by inhibiting glucose reabsorption in the kidneys, leading to a sustained reduction in insulin levels. The medication has been approved in Great Britain and represents Boehringer Ingelheim's commitment to advancing equine health through innovative treatments. The company highlights the significant unmet need for therapies addressing this debilitating condition in horses.

CREDIT: Boehringer Ingelheim
Original release on GlobeNewswire